Journal ArticleDOI
Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement
René Adam,Robbert J. de Haas,Dennis A. Wicherts,Thomas A. Aloia,V. Delvart,Daniel Azoulay,Henri Bismuth,D. Castaing +7 more
Reads0
Chats0
TLDR
Combined liver resection and pedicular lymphadenectomy is justified when RLN metastases respond to or are stabilized by preoperative chemotherapy, particularly in young patients, but this approach does not benefit patients with celiac and/or para-aortic RLN involvement, even when patients' disease is responding to preoperatively chemotherapy.Abstract:
Purpose For patients with colorectal liver metastases (CLM), regional lymph node (RLN) involvement is one of the worst prognostic factors. The objective of this study was to evaluate the ability of a multidisciplinary approach, including preoperative chemotherapy and hepatectomy, to improve patient outcomes. Patients and Methods Outcomes for a consecutively treated group of patients with CLM and simultaneous RLN involvement were compared with a cohort of patients without RLN involvement. Univariate and multivariate analysis of clinical variables was used to identify prognostic factors in this high-risk group. Results Of the 763 patients who underwent resection at our institution for CLM between 1992 and 2006, 47 patients (6%) were treated with hepatectomy and simultaneous lymphadenectomy. All patients had received preoperative chemotherapy. Five-year overall survival (OS) for patients with and without RLN involvement were 18% and 53%, respectively (P < .001). Five-year disease-free survival rates were 11%...read more
Citations
More filters
Journal ArticleDOI
World review of laparoscopic liver resection-2,804 patients.
TL;DR: In experienced hands, laparoscopic liver resections are safe with acceptable morbidity and mortality for both minor and major hepatic resection, albeit in a selected group of patients.
Journal ArticleDOI
Comparative benefits of laparoscopic vs open hepatic resection: a critical appraisal.
TL;DR: In this paper, the authors performed a literature review examining the comparative benefits of laparoscopic vs open hepatic resection and to define the benefits and outcomes of Laparoscopic liver resection in their own series of 314 patients.
Journal ArticleDOI
Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis
Laura Rubbia-Brandt,Gregory Y. Lauwers,Huamin Wang,Pietro Majno,Kenneth K. Tanabe,Andrew X. Zhu,Catherine Brezault,Olivier Soubrane,Eddie K Abdalla,Jean Nicolas Vauthey,Gilles Mentha,Benoit Terris +11 more
TL;DR: Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin‐associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.
Journal ArticleDOI
Minimally invasive liver resection for metastatic colorectal cancer: a multi-institutional, international report of safety, feasibility, and early outcomes.
Kevin Nguyen,Alexis Laurent,Ibrahim Dagher,David A. Geller,Jennifer L. Steel,Mark T. Thomas,Michael R. Marvin,Kadiyala V. Ravindra,Alejandro Mejia,Panagiotis Lainas,Dominique Franco,Daniel Cherqui,Joseph F. Buell,T. Clark Gamblin +13 more
TL;DR: Minimally invasive liver resection for colorectal metastasis is safe, feasible, and oncologically comparable to open liver resections, even with prior intra-abdominal operations, in selected patients and when performed by experienced surgeons.
Journal ArticleDOI
Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population‐based series
A. E. M. van der Pool,Ronald A. M. Damhuis,J. N. M. Ijzermans,J.H.W. de Wilt,Alexander M.M. Eggermont,Ries Kranse,Cornelis Verhoef +6 more
TL;DR: The incidence, patterns of care and survival were determined in patients with stage IV colorectal cancer in a population‐based series and the results confirmed the need for further research into the determinants of survival and disease progression.
References
More filters
BookDOI
TNM classification of malignant tumours
TL;DR: Head and Neck Tumours.- Lip and Oral Cavity.- Pharynx.- Larynx.' Maxillary Sinus.- Salivary Glands.- Thyroid Gland.- Digestive System Tumour .
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Herbert Hurwitz,Louis Fehrenbacher,William Novotny,Thomas Cartwright,John D. Hainsworth,W. Heim,Jordan Berlin,Ari David Baron,Susan Griffing,Eric Holmgren,Napoleone Ferrara,Gwen Fyfe,Beth Rogers,Robert W. Ross,Fairooz F. Kabbinavar +14 more
TL;DR: The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer.
Journal ArticleDOI
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
David Cunningham,Yves Humblet,Salvatore Siena,David Khayat,Harry Bleiberg,Armando Santoro,D. Bets,M. Mueser,Andreas Harstrick,Chris Verslype,Ian Chau,Eric Van Cutsem +11 more
TL;DR: Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with ir inotecans-refractory colorectal cancer.
Journal ArticleDOI
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
A. de Gramont,A. Figer,M. Seymour,M. Homerin,A. Hmissi,J. Cassidy,Corrado Boni,H. Cortes-Funes,Andrés Cervantes,Gilles Freyer,Demetris Papamichael,N. Le Bail,C. Louvet,D. Hendler,F. de Braud,C. Wilson,Francois Morvan,Andrea Bonetti +17 more
TL;DR: The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progression-free survival with acceptable tolerability and maintenance of QoL.
Related Papers (5)
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
Bernard Nordlinger,Halfdan Sorbye,Bengt Glimelius,Bengt Glimelius,Graeme J. Poston,Peter M. Schlag,Philippe Rougier,Wolf O. Bechstein,John N. Primrose,Euan Walpole,Meg Finch-Jones,Daniel Jaeck,Darius F. Mirza,Rowan W. Parks,Laurence Collette,M. Praet,U. Bethe,Eric Van Cutsem,Werner Scheithauer,Thomas Gruenberger +19 more